Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Carol Mansfield, Mirko V. Sikirica, Amy Pugh, Christine M. Poulos, Victoria Unmuessig, Raul Morano, Alan A. Martin

ABSTRACT

INTRODUCTION: Understanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors. In this survey, we quantified the relative preferences among patients in Germany and Spain in separate analyses. METHODS: A stated-preference, discrete-choice experiment (DCE) survey was designed to elicit preferences for T2DM treatment attributes among patients with self-reported T2DM and who reported being prescribed T2DM medication for > 2 years. Patients recruited from an online national consumer panel completed an online survey. The survey presented choices between eight pairs of hypothetical T2DM treatments defined by seven attributes: chance of reaching target hemoglobin A1c (HbA1c) level; reduced risk of serious heart attack or stroke; frequency of hypoglycemia; risk of gastrointestinal (GI) problems; weight change; mode of administration (oral or injectable); dosing frequency. Data were analyzed using random-parameters logit. Minimum acceptable benefit (MAB) was defined as the minimum increase in the probability of reaching target HbA1c for which respondents would accept less desirable levels of other attributes. RESULTS: In Germany and Spain, 474 and 401 respondents completed the survey, respectively. DCE analysis showed that risk of GI problems was most important to German respondents. MAB analysis found that respondents would require a 56 percentage point increase in the probability of reaching their HbA1c target to offset a change from 0% to 30% risk of GI problems. For Spanish respondents, mode of administration was the most important attribute. These respondents would require a 59 percentage point increase in the probability of reaching their HbA1c target to offset moving from oral to injectable medications. CONCLUSIONS: Respondents in Germany and Spain were willing to trade efficacy for improvements in side effects and mode of administration. Given the variety of T2DM medications currently available, the results suggest that careful discussion about patient preferences could help improve patient satisfaction with T2DM treatment. More... »

PAGES

1365-1378

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-017-0326-8

DOI

http://dx.doi.org/10.1007/s13300-017-0326-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092516417

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29101681


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mansfield", 
        "givenName": "Carol", 
        "id": "sg:person.011705723124.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011705723124.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GlaxoSmithKline, Collegeville, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sikirica", 
        "givenName": "Mirko V.", 
        "id": "sg:person.01012533571.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012533571.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA", 
            "San Francisco School of Medicine, University of California, San Francisco, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pugh", 
        "givenName": "Amy", 
        "id": "sg:person.01247230713.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247230713.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poulos", 
        "givenName": "Christine M.", 
        "id": "sg:person.01320763315.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320763315.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420105.2", 
          "name": [
            "GlaxoSmithKline, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Unmuessig", 
        "givenName": "Victoria", 
        "id": "sg:person.01067732673.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067732673.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Spain)", 
          "id": "https://www.grid.ac/institutes/grid.419327.a", 
          "name": [
            "GlaxoSmithKline, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morano", 
        "givenName": "Raul", 
        "id": "sg:person.01044236642.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044236642.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418236.a", 
          "name": [
            "GlaxoSmithKline, Brentford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin", 
        "givenName": "Alan A.", 
        "id": "sg:person.015327347602.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015327347602.22"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.diabet.2013.06.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004451238"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/014572170403000223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006040472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/014572170403000223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006040472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-014-0170-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014604000", 
          "https://doi.org/10.1007/s40273-014-0170-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/1-4020-3684-1_7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015379515", 
          "https://doi.org/10.1007/1-4020-3684-1_7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc13-2527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017114608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc14-2441", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021071301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-013-0046-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022035467", 
          "https://doi.org/10.1007/s13300-013-0046-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ppa.s43465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024271928"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1753-0407.12524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024731469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1753-0407.12524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024731469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djr318", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025967266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026425084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2010.11.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030781921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-011-2336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036112369", 
          "https://doi.org/10.1007/s00125-011-2336-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-011-2336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036112369", 
          "https://doi.org/10.1007/s00125-011-2336-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10654-012-9726-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036959678", 
          "https://doi.org/10.1007/s10654-012-9726-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2012.08.2223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037115565"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4158/ep151126.cs", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043462423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabres.2013.11.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049012856"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1932296816633232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052819598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1932296816633232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052819598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.28.9.2243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053371382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/cbo9780511610356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1098712532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/cbo9780511753930", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1098721478"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "INTRODUCTION: Understanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors. In this survey, we quantified the relative preferences among patients in Germany and Spain in separate analyses.\nMETHODS: A stated-preference, discrete-choice experiment (DCE) survey was designed to elicit preferences for T2DM treatment attributes among patients with self-reported T2DM and who reported being prescribed T2DM medication for\u00a0>\u00a02\u00a0years. Patients recruited from an online national consumer panel completed an online survey. The survey presented choices between eight pairs of hypothetical T2DM treatments defined by seven attributes: chance of reaching target hemoglobin A1c (HbA1c) level; reduced risk of serious heart attack or stroke; frequency of hypoglycemia; risk of gastrointestinal (GI) problems; weight change; mode of administration (oral or injectable); dosing frequency. Data were analyzed using random-parameters logit. Minimum acceptable benefit (MAB) was defined as the minimum increase in the probability of reaching target HbA1c for which respondents would accept less desirable levels of other attributes.\nRESULTS: In Germany and Spain, 474 and 401 respondents completed the survey, respectively. DCE analysis showed that risk of GI problems was most important to German respondents. MAB analysis found that respondents would require a 56 percentage point increase in the probability of reaching their HbA1c target to offset a change from 0% to 30% risk of GI problems. For Spanish respondents, mode of administration was the most important attribute. These respondents would require a 59 percentage point increase in the probability of reaching their HbA1c target to offset moving from oral to injectable medications.\nCONCLUSIONS: Respondents in Germany and Spain were willing to trade efficacy for improvements in side effects and mode of administration. Given the variety of T2DM medications currently available, the results suggest that careful discussion about patient preferences could help improve patient satisfaction with T2DM treatment.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-017-0326-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey", 
    "pagination": "1365-1378", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "835fff40dd99a3f65e3cc9489cc2e93e93dd094b50ecbc79b97835ea1da6e766"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29101681"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-017-0326-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092516417"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-017-0326-8", 
      "https://app.dimensions.ai/details/publication/pub.1092516417"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000575.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs13300-017-0326-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0326-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0326-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0326-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0326-8'


 

This table displays all metadata directly associated to this object as RDF triples.

195 TRIPLES      21 PREDICATES      50 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-017-0326-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N3b9b742921344d20b41e1dee9036a679
4 schema:citation sg:pub.10.1007/1-4020-3684-1_7
5 sg:pub.10.1007/s00125-011-2336-9
6 sg:pub.10.1007/s10654-012-9726-2
7 sg:pub.10.1007/s13300-013-0046-7
8 sg:pub.10.1007/s40273-014-0170-x
9 https://doi.org/10.1016/j.diabet.2013.06.001
10 https://doi.org/10.1016/j.diabres.2013.11.007
11 https://doi.org/10.1016/j.jval.2010.11.013
12 https://doi.org/10.1016/j.jval.2012.08.2223
13 https://doi.org/10.1017/cbo9780511610356
14 https://doi.org/10.1017/cbo9780511753930
15 https://doi.org/10.1093/jnci/djr318
16 https://doi.org/10.1111/1753-0407.12524
17 https://doi.org/10.1111/dom.12679
18 https://doi.org/10.1177/014572170403000223
19 https://doi.org/10.1177/1932296816633232
20 https://doi.org/10.2147/ppa.s43465
21 https://doi.org/10.2337/dc13-2527
22 https://doi.org/10.2337/dc14-2441
23 https://doi.org/10.2337/diacare.28.9.2243
24 https://doi.org/10.4158/ep151126.cs
25 schema:datePublished 2017-12
26 schema:datePublishedReg 2017-12-01
27 schema:description INTRODUCTION: Understanding patient preferences for attributes of type 2 diabetes mellitus (T2DM) medications may help explain how the attributes differentially affect patient perceptions and behaviors. In this survey, we quantified the relative preferences among patients in Germany and Spain in separate analyses. METHODS: A stated-preference, discrete-choice experiment (DCE) survey was designed to elicit preferences for T2DM treatment attributes among patients with self-reported T2DM and who reported being prescribed T2DM medication for > 2 years. Patients recruited from an online national consumer panel completed an online survey. The survey presented choices between eight pairs of hypothetical T2DM treatments defined by seven attributes: chance of reaching target hemoglobin A1c (HbA1c) level; reduced risk of serious heart attack or stroke; frequency of hypoglycemia; risk of gastrointestinal (GI) problems; weight change; mode of administration (oral or injectable); dosing frequency. Data were analyzed using random-parameters logit. Minimum acceptable benefit (MAB) was defined as the minimum increase in the probability of reaching target HbA1c for which respondents would accept less desirable levels of other attributes. RESULTS: In Germany and Spain, 474 and 401 respondents completed the survey, respectively. DCE analysis showed that risk of GI problems was most important to German respondents. MAB analysis found that respondents would require a 56 percentage point increase in the probability of reaching their HbA1c target to offset a change from 0% to 30% risk of GI problems. For Spanish respondents, mode of administration was the most important attribute. These respondents would require a 59 percentage point increase in the probability of reaching their HbA1c target to offset moving from oral to injectable medications. CONCLUSIONS: Respondents in Germany and Spain were willing to trade efficacy for improvements in side effects and mode of administration. Given the variety of T2DM medications currently available, the results suggest that careful discussion about patient preferences could help improve patient satisfaction with T2DM treatment.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N096f5f912d954fcc87f5d5d4c0c3259b
32 Nc84c7c9909664fc0883aa5c02eb84e26
33 sg:journal.1044057
34 schema:name Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey
35 schema:pagination 1365-1378
36 schema:productId N1494ede6dd50448da353a87229e4ea6c
37 N3f669060ce2a49cb87596636f811867d
38 N59a55063d2f548dfa5dc80c6addce575
39 N7533ce3c632e4ac48d6eded6d19e910e
40 Ncf2e71d74911435ead5ef9690e1edd6d
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092516417
42 https://doi.org/10.1007/s13300-017-0326-8
43 schema:sdDatePublished 2019-04-10T15:11
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher N4df0388d4c32462483fdbcfc967187f5
46 schema:url https://link.springer.com/10.1007%2Fs13300-017-0326-8
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N096f5f912d954fcc87f5d5d4c0c3259b schema:volumeNumber 8
51 rdf:type schema:PublicationVolume
52 N0b6fe29838a64f15821c688168c67e6f rdf:first sg:person.01067732673.78
53 rdf:rest N905b1aee4a964aa5bfe5622b0cc818a4
54 N1494ede6dd50448da353a87229e4ea6c schema:name pubmed_id
55 schema:value 29101681
56 rdf:type schema:PropertyValue
57 N3b9b742921344d20b41e1dee9036a679 rdf:first sg:person.011705723124.99
58 rdf:rest Nbf11b3c30b6049e7b9d084d052d978e8
59 N3f669060ce2a49cb87596636f811867d schema:name dimensions_id
60 schema:value pub.1092516417
61 rdf:type schema:PropertyValue
62 N420213ef4b0c46f4968988153b023568 rdf:first sg:person.01320763315.66
63 rdf:rest N0b6fe29838a64f15821c688168c67e6f
64 N4df0388d4c32462483fdbcfc967187f5 schema:name Springer Nature - SN SciGraph project
65 rdf:type schema:Organization
66 N59a55063d2f548dfa5dc80c6addce575 schema:name nlm_unique_id
67 schema:value 101539025
68 rdf:type schema:PropertyValue
69 N62ab190e379f43e0bf4fe72f3d1a6859 rdf:first sg:person.01247230713.87
70 rdf:rest N420213ef4b0c46f4968988153b023568
71 N7533ce3c632e4ac48d6eded6d19e910e schema:name readcube_id
72 schema:value 835fff40dd99a3f65e3cc9489cc2e93e93dd094b50ecbc79b97835ea1da6e766
73 rdf:type schema:PropertyValue
74 N905b1aee4a964aa5bfe5622b0cc818a4 rdf:first sg:person.01044236642.08
75 rdf:rest N94f5b510c03447e4bc19115330486852
76 N94f5b510c03447e4bc19115330486852 rdf:first sg:person.015327347602.22
77 rdf:rest rdf:nil
78 Nbf11b3c30b6049e7b9d084d052d978e8 rdf:first sg:person.01012533571.12
79 rdf:rest N62ab190e379f43e0bf4fe72f3d1a6859
80 Nc84c7c9909664fc0883aa5c02eb84e26 schema:issueNumber 6
81 rdf:type schema:PublicationIssue
82 Ncf2e71d74911435ead5ef9690e1edd6d schema:name doi
83 schema:value 10.1007/s13300-017-0326-8
84 rdf:type schema:PropertyValue
85 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
86 schema:name Medical and Health Sciences
87 rdf:type schema:DefinedTerm
88 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
89 schema:name Clinical Sciences
90 rdf:type schema:DefinedTerm
91 sg:journal.1044057 schema:issn 1869-6953
92 1869-6961
93 schema:name Diabetes Therapy
94 rdf:type schema:Periodical
95 sg:person.01012533571.12 schema:affiliation https://www.grid.ac/institutes/grid.418019.5
96 schema:familyName Sikirica
97 schema:givenName Mirko V.
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012533571.12
99 rdf:type schema:Person
100 sg:person.01044236642.08 schema:affiliation https://www.grid.ac/institutes/grid.419327.a
101 schema:familyName Morano
102 schema:givenName Raul
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044236642.08
104 rdf:type schema:Person
105 sg:person.01067732673.78 schema:affiliation https://www.grid.ac/institutes/grid.420105.2
106 schema:familyName Unmuessig
107 schema:givenName Victoria
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067732673.78
109 rdf:type schema:Person
110 sg:person.011705723124.99 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
111 schema:familyName Mansfield
112 schema:givenName Carol
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011705723124.99
114 rdf:type schema:Person
115 sg:person.01247230713.87 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
116 schema:familyName Pugh
117 schema:givenName Amy
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247230713.87
119 rdf:type schema:Person
120 sg:person.01320763315.66 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
121 schema:familyName Poulos
122 schema:givenName Christine M.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320763315.66
124 rdf:type schema:Person
125 sg:person.015327347602.22 schema:affiliation https://www.grid.ac/institutes/grid.418236.a
126 schema:familyName Martin
127 schema:givenName Alan A.
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015327347602.22
129 rdf:type schema:Person
130 sg:pub.10.1007/1-4020-3684-1_7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015379515
131 https://doi.org/10.1007/1-4020-3684-1_7
132 rdf:type schema:CreativeWork
133 sg:pub.10.1007/s00125-011-2336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036112369
134 https://doi.org/10.1007/s00125-011-2336-9
135 rdf:type schema:CreativeWork
136 sg:pub.10.1007/s10654-012-9726-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036959678
137 https://doi.org/10.1007/s10654-012-9726-2
138 rdf:type schema:CreativeWork
139 sg:pub.10.1007/s13300-013-0046-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022035467
140 https://doi.org/10.1007/s13300-013-0046-7
141 rdf:type schema:CreativeWork
142 sg:pub.10.1007/s40273-014-0170-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1014604000
143 https://doi.org/10.1007/s40273-014-0170-x
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/j.diabet.2013.06.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004451238
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1016/j.diabres.2013.11.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049012856
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1016/j.jval.2010.11.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030781921
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1016/j.jval.2012.08.2223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037115565
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1017/cbo9780511610356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1098712532
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1017/cbo9780511753930 schema:sameAs https://app.dimensions.ai/details/publication/pub.1098721478
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1093/jnci/djr318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025967266
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1111/1753-0407.12524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024731469
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1111/dom.12679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026425084
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1177/014572170403000223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006040472
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1177/1932296816633232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052819598
166 rdf:type schema:CreativeWork
167 https://doi.org/10.2147/ppa.s43465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024271928
168 rdf:type schema:CreativeWork
169 https://doi.org/10.2337/dc13-2527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017114608
170 rdf:type schema:CreativeWork
171 https://doi.org/10.2337/dc14-2441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021071301
172 rdf:type schema:CreativeWork
173 https://doi.org/10.2337/diacare.28.9.2243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053371382
174 rdf:type schema:CreativeWork
175 https://doi.org/10.4158/ep151126.cs schema:sameAs https://app.dimensions.ai/details/publication/pub.1043462423
176 rdf:type schema:CreativeWork
177 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
178 schema:name RTI Health Solutions, Research Triangle Park, NC, USA
179 San Francisco School of Medicine, University of California, San Francisco, USA
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.418019.5 schema:alternateName GlaxoSmithKline (United States)
182 schema:name GlaxoSmithKline, Collegeville, PA, USA
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.418236.a schema:alternateName GlaxoSmithKline (United Kingdom)
185 schema:name GlaxoSmithKline, Brentford, UK
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.419327.a schema:alternateName GlaxoSmithKline (Spain)
188 schema:name GlaxoSmithKline, Madrid, Spain
189 rdf:type schema:Organization
190 https://www.grid.ac/institutes/grid.420105.2 schema:alternateName GlaxoSmithKline (Germany)
191 schema:name GlaxoSmithKline, Munich, Germany
192 rdf:type schema:Organization
193 https://www.grid.ac/institutes/grid.62562.35 schema:alternateName RTI International
194 schema:name RTI Health Solutions, Research Triangle Park, NC, USA
195 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...